Tchaikapharma High Quality Medicines AD First Quarter 2024 Earnings: EPS: лв0.02 (vs лв0.022 in 1Q 2023)

Tchaikapharma High Quality Medicines AD (BUL:THQM) First Quarter 2024 Results

Key Financial Results

• Revenue: лв13.4m (down 1.8% from 1Q 2023).
• Net income: лв1.47m (down 24% from 1Q 2023).
• Profit margin: 11% (down from 14% in 1Q 2023). The decrease in margin was primarily driven by higher expenses.
• EPS: лв0.02 (down from лв0.022 in 1Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Tchaikapharma High Quality Medicines AD's share price is broadly unchanged from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 2 warning signs for Tchaikapharma High Quality Medicines AD you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.